Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 5/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | IGF1R | P08069 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.39 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14394157 | 0.92 | CLK4 (0.37) | AURKARPS6KB1AURKBDHFRCLK4 | |
| SCHEMBL5416533 | 0.85 | CLK4 (0.52) | CLK4DYRK1AMAPTMEN1KMT2A | |
| SCHEMBL20814215 | 0.74 | MAPT (0.47) | DHFRLMNAALDH1A1TSHRCYP1A2 | |
| SCHEMBL3143358 | 0.74 | CDK2 (0.57) | LMNAALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5207658 | 0.74 | CLK4 (0.51) | RPS6KB1AURKBCLK4DYRK1AALDH1A1 | |
| SCHEMBL6283187 | 0.73 | MAP4K4 (0.48) | MEN1KMT2A | |
| SCHEMBL3266578 | 0.73 | ENPP2 (0.41) | ABCB1CYP1A1CYP1B1 | |
| SCHEMBL5209249 | 0.73 | FYN (0.61) | — | |
| SCHEMBL22792194 | 0.72 | TSHR (0.50) | CLK4ABCB1LMNAALDH1A1TSHR | |
| SCHEMBL3140863 | 0.72 | KDM4E (0.58) | ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1513821-B1 | PROTEIN KINASE INHIBITORS | CYTOPIA PTY LTD (AU) | 2007-10-31 | — | — | EP | disclosed |
| US-7122550-B2 | Protein kinase inhibitors | CYTOPIA PTY LTD (AU) | 2006-10-17 | — | — | US | disclosed |
| US-20060148824-A1 | Protein kinase inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2006-07-06 | — | — | US | disclosed |
| US-20040235862-A1 | For therapy of atopy, a cell mediated hypersensitivity, a rheumatic disease, an autoimmune disease, a viral disease, and a cancer | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235862-A1 | For therapy of atopy, a cell mediated hypersensitivity, a rheumatic disease, an autoimmune disease, a viral disease, and a cancer | LCK, IRAK1, MAP2K5 | AURKA 146/4885RPS6KB1 712/4885AURKB 241/4885 |
| US-20060148824-A1 | Protein kinase inhibitors | MAP3K20, MAP4K2, MAP3K1 | AURKA 273/4885RPS6KB1 240/4885AURKB 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.